|
15 Feb 2026 |
Indegene
|
Consensus Share Price Target
|
474.70 |
605.86 |
- |
27.63 |
buy
|
|
|
|
|
31 Jan 2026
|
Indegene
|
Motilal Oswal
|
474.70
|
550.00
|
482.40
(-1.60%)
|
15.86 |
Neutral
|
|
|
Indegene’s 3QFY26 USD revenue rose 15.1% QoQ, aided by the BioPharm acquisition, while organic USD revenue growth stood at 4% QoQ (below our estimate).
|
|
10 Jul 2024
|
Indegene
|
Monarch Networth Capital Limited
|
474.70
|
660.00
|
569.95
(-16.71%)
|
Target met |
Buy
|
|
|
|
|
03 May 2024
|
Indegene
|
HDFC Securities
|
474.70
|
|
|
|
IPO Note
|
|
|
IPO Note - Indegene Limited Indegene Limited (IL) provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products
|
|
03 May 2024
|
Indegene
|
Ventura
|
474.70
|
|
|
|
IPO Subscribe
|
|
|
|
|
03 May 2024
|
Indegene
|
Ashika Research
|
474.70
|
|
|
|
IPO Note
|
|
|
|
|
03 May 2024
|
Indegene
|
SBI Securities
|
474.70
|
|
|
|
IPO Subscribe
|
|
|
|
|
02 May 2024
|
Indegene
|
Hem Securities
|
474.70
|
|
|
|
IPO Subscribe
|
|
|
|